Cancer-causing ingredients found in popular protein powders
Nearly half of the most popular protein powders on the market tested positive for higher-than-safe levels of heavy metals, ...
Mersana falls after early-stage trial data for lead cancer therapy
Mersana Therapeutics (MRSN) stock hits a 52-week low in reaction to early clinical results for its cancer drug Emi-Le in ...
Mersana Therapeutics, Inc.: Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...
FierceBiotech3h
Insilico Medicine licenses 2nd AI-generated cancer drug candidate to Menarini’s Stemline in $550M deal
Another new year, another half-billion-biobuck transaction between Insilico Medicine and the Italian drugmaker Menarini Group ...
News Medical3h
Machine learning reveals why cancer trials fall short in real-world patients
TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients ...
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based ...
Medscape4h
Metronomic Capecitabine Plus Aromatase Inhibitor Boosts Survival in HR+ Breast Cancer
Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either ...
Mersana Shares Rise on Advances With Breast-Cancer Treatment
Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...
Mersana Therapeutics: FDA Grants Additional Fast Track Designation To XMT-1660
Mersana Therapeutics (MRSN) announced the FDA recently granted an additional Fast Track designation to XMT-1660. The new Fast Track ...
Healio5h
Adding camrelizumab to chemotherapy improves outcomes in triple-negative breast cancer
The addition of camrelizumab to platinum-containing intensive neoadjuvant chemotherapy improved pathologic complete response ...
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ETCAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE ...
National Health Executive5h
NICE recommends new breast cancer treatment
NICE's endorsement of olaparib, produced by AstraZeneca, marks a crucial step forward in the treatment of breast cancer. This ...